ALNOV:EPA
Novacyt SA
€0.46
arrow_upward
+1.20%(+0.0055) 1D
Oct 23, 5:35:29 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.46
High
€0.48
Low
€0.46
Mkt. cap
32.46M
Avg. vol.
192.39K
Volume
160.58K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
Open
€0.46
High
€0.48
Low
€0.46
Mkt. cap
32.46M
Avg. vol.
192.39K
Volume
160.58K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
Trefis
·
1 hour ago
18 S&P 500 Stocks Just Made New 52-Week Highs
Around Prague
·
11 hours ago
What Oil Near $117 and a Dow Slide Mean for Gas, Mortgages and Prices
UA.NEWS
·
11 hours ago
Dow Jones falls 1.2% amid concerns over AI spending — The Rio Times
The Cryptonomist
·
4 hours ago
Vanguard S&P 500 ETF Analysis Closes at $698.58
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and VĂ©lizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA